# AENEAS

Source: https://onco.cc/trials/aeneas/  
OnCo record `aeneas` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The trial that showed Hansoh's aumolertinib roughly doubles progression-free survival compared with gefitinib in EGFR-mutant lung cancer.

## Summary

429 patients, double blind. Median progression-free survival 19.3 versus 9.9 months (hazard ratio 0.46), consistent across exon 19 and L858R subgroups and in patients with brain metastases; published in the Journal of Clinical Oncology 2022. NMPA first-line approval December 2021. Aumolertinib has since become one of the most prescribed targeted drugs in China.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-10
- Tags: china
- Registry id: NCT03849768
- Phase: 3
- Setting: First-line EGFR-mutant (exon 19 deletion or L858R) locally advanced or metastatic NSCLC, China: aumolertinib vs gefitinib
- Sponsor: Hansoh Pharmaceutical
- Enrolled: 429
- Result: PFS 19.3 vs 9.9 months, HR 0.46.
- Outcomes: Progression-free survival: Aumolertinib 19.3 months vs Gefitinib 9.9 months, HR 0.46

## Sources

- ClinicalTrials.gov NCT03849768: https://clinicaltrials.gov/study/NCT03849768
- J Clin Oncol 2022: https://doi.org/10.1200/JCO.21.02641

## Connected records

- trials: [FURLONG](https://onco.cc/trials/furlong/)
- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- drugs: [Aumolertinib](https://onco.cc/drugs/aumolertinib/), [Gefitinib](https://onco.cc/drugs/gefitinib/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/)
- key papers: [AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations](https://onco.cc/key-papers/paper-aeneas-j-clin-oncol-2022/)

---
JSON: https://onco.cc/api/v1/entities/aeneas.json